Latus Bio develops gene therapy candidates, particularly for treating central nervous system (CNS) disorders using screened AAV capsids.
Latus Bio has raised $43.0M in total funding. The most recent round was Series A. The last funding was announced in May 2026.
Latus Bio's investors include Gaingels, 8VC, DCVC Bio, Modi Ventures, BioAdvance.
Latus Bio is headquartered in Philadelphia, United States.
Latus Bio develops gene therapy candidates, particularly for treating central nervous system (CNS) disorders using screened AAV capsids.
Latus Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Latus Bio — Funding & Investors." VCBacked, May 4, 2026, https://www.vcbacked.co/company/latus-bio. Accessed September 1, 2026.
VCBacked. (2026). Latus Bio — Funding & Investors. Retrieved September 1, 2026, from https://www.vcbacked.co/company/latus-bio
{{cite web |title=Latus Bio — Funding & Investors |url=https://www.vcbacked.co/company/latus-bio |website=VCBacked |access-date=September 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated